Skip to main content
Sign In

Dr. Klopper joined the faculty of the Division of Endocrinology, Metabolism and Diabetes in July 2006. Dr. Klopper was born and raised in Atlanta, GA. His educational background includes a B.S. in Psychology in 1995 from Indiana University in Bloomington, IN. He received his medical degree from the Emory University School of Medicine in Atlanta, GA in 1999. He relocated to Colorado in 1999 where he completed his internship and residency in internal medicine at the University of Colorado Health Sciences Center in 2002. Dr. Klopper then did a postdoctoral research fellowship in the Endocrinology Division from 2002-2003 prior to starting his endocrinology fellowship at UCDHSC which he completed in June 2006.

Dr. Klopper’s research interests are in the treatment of poorly differentiated thyroid cancer by the investigation of molecular targets in the nuclear hormone receptor superfamily. Specifically he is investigating the activation of retinoid, PPARγ and Vitamin D receptors to inhibit cell growth and potentially induce redifferentiation in aggressive thyroid cancers.

Dr. Klopper attends in the University of Colorado endocrinology clinic one day a week and in the multidisciplinary advanced thyroid oncology clinic at the University of Colorado Cancer Center one afternoon a month.

Selected Publications 

  • Klopper JP, Sharma V, Bissonnette R, Haugen BR. Combination PPARgamma and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2. PPAR Res. 2010;2010:729876. PUBMED
  • Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8. PUBMED
  • Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Mol Cancer. 2009 Mar 6;8:16. PUBMED
  • Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC, Haugen BR. DNA Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting In Cell Line Redundancy And Misidentification
    J Clin Endocrinol Metab. 2008 PUBMED
  • Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Singh M, Bissonnette RP, Haugen BR. In Vivo and Microarray Analysis of Rexinoid Responsive Anaplastic Thyroid Carcinoma. Clin Cancer Res. 2008 Jan 15;14(2):589-96 PUBMED
  • Klopper JP, McDermott MT. Palpable pediatric thyroid abnormalities - diagnostic pitfalls necessitate a high index of clinical suspicion: a case report. J Med Case Reports. 2007 Jun 22;1(1):29 PUBMED
  • Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13;25(16):2304-17. PUBMED
  • Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM and Haugen BR. 2004 RXRg and PPARg expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 2004 3: 1011-1020. PUBMED
  • Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab. 2004 Jan;89(1):272-80. PUBMED 


Coming Soon!

Reasearch Interests

  • Thyroid nodules and cancer
  • Thyroid Disease
  • Metabolic Bone Disease